1. X
  2. Genentech
Log inSign up
Genentech
7,810 posts
Image
user avatar
Genentech
@genentech
Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
USA
gene.com
Joined September 2008
225
Following
123.2K
Followers
RepliesRepliesMediaMedia
  • user avatar
    Genentech
    @genentech
    Jul 15
    #Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more:
    Image
    00:00
  • user avatar
    Genentech
    @genentech
    Jul 7
    #Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: gene.com/media/press-re…
    Image
    00:00
  • user avatar
    Genentech
    @genentech
    Jul 2
    #Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-re…
    Image
    00:00
  • user avatar
    Genentech
    @genentech
    Jun 30
    #Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: gene.com/media/press-re…
    Image
  • user avatar
    Genentech
    @genentech
    Jun 18
    #Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: gene.com/media/press-re…
    Image
    00:00

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Advertisement
Advertisement